o In March 2022, there was a marked decrease in COVID-19 case incidence, deaths and laboratory tests conducted. Libya continued to be classified as having a high incidence of community transmission (CT3) with six cases/100 000 population/week, with the circulation of Alpha, Beta, Delta and Omicron variants of concern. The weekly test positivity rate was 6.9%.
o As of 15 March 2022, a total of a cumulative 8 950 720 vaccine doses (all sources) had been received in the country, of which 3.8 million (42%) were estimated to have been utilized (wastage adjusted). Available vaccine stocks are estimated to be 5 million doses.
o WHO coordinated between the ministries of health of Libya and Turkey to facilitate the participation of the Deputy Prime Minister of Libya in a high-level meeting on health and migration in the WHO European Region to be held in Istanbul, Turkey from 17 to 18 March 2022.